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Available online 7 July 2016Objectives: Trials of remote ischemic pre-conditioning (RIPC) have suggested this intervention reduces complica-
tions of percutaneous coronary intervention and coronary by-pass surgery. The aims of thisworkwere to (i) con-
duct a systematic review and meta-analysis of the effects of RIPC on cardiac and renal damage in patients
undertaking elective percutaneous coronary intervention (PCI); (ii) summarize the results in an evidence-
based clinical context.
Methods:We conducted a systematic search of published randomized controlled trials of RIPC for elective PCI up
until May 1st, 2015. Studies of peri- or post-ischemic conditioning or emergency PCI were excluded.
Results:Nine studies, totalling 1253 patients were included. Compared to control, RIPC groups exhibited reduced
peri-procedural myocardial infarction (MI) Odds Ratio (OR) 0.72 (95% CI 0.54 to 0.97, p=0.03); ST-segment de-
viation OR 0.42 (95% CI 0.28 to 0.63, p b 0.0001); major adverse cardiac events (MACE) OR 0.41 (95% CI 0.21 to
0.84, p = 0.01); and acute kidney injury (AKI) OR 0.47 (95% CI 0.26 to 0.86, p = 0.01), but not mortality OR
1.00 (95% CI 0.27 to 3.73, p= 1.00).
Conclusions: RIPC is likely to prevent major adverse cardiac and renal events in patients undertaking elective PCI.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Remote ischemic pre-conditioning
Elective percutaneous intervention
Major adverse cardiac events
Acute kidney injury1. Introduction
Coronary artery disease (CAD) is associatedwith the development of
atherosclerotic plaques in the coronary arteries. Percutaneous coronary
intervention (PCI) is one of the major treatment options used to relieve
CAD symptoms, prevent myocardial infarction and in the immediate
treatment ofmyocardial infarction.Unfortunately re-opening of a previ-
ously partially or completely occluded coronary vessel exposes the
myocardium to ischemia reperfusion injury.
Remote ischaemic pre-conditioning (RIPC) relates to short se-
quences of ischemia, usually 4–5 min, of repeated blood pressure cuff
inﬂation and deﬂation on a limb. Short periods of ischemia trigger cellu-
lar signalling pathways that protect against a subsequent longer period
of ischemia, such as during PCI. RIPC is one of the most effective tech-
niques of protecting the heart against ischemia reperfusion injury. Thery artery disease; IPC, ischemic
MI, myocardial infarction; PCI,
aemic pre-conditioning; RCT,
.
eliability and freedom from bias
. This is an open access article underRIPC process usually involves 3–4 cycles of repeated inﬂation-deﬂation
lasting about 25–30min [1]. RIPC has become increasingly attractive be-
cause it is relatively simple to administer and is non-invasive.Moreover,
RIPC can be administered during natural waiting periods as patients
enter the catheter lab for PCI. RIPC has been used in both upper and
lower limbs and offers cardio-protection for those undergoing percuta-
neous coronary revascularization [2]. RIPC has also been found to reduce
acute kidney injury in those exposed to contrast media [3] and infarct
size by administering RIPC during transport to the medical centre
prior to cardiac surgery [4]. More recent work has examined the cumu-
lative effects of repeated RIPC treatments tomanage blood pressure [5],
improve endothelial function and blood ﬂow [6].
The effects of RIPC may extend beyond the tissues exposed to cuff
occlusion, with recent reports suggesting a neuroprotective effect that
improved tolerance to cerebral ischemia [7]. RIPC induced neuroprotec-
tion by attenuating adenosine 5′-monophosphate-activated protein ki-
nase [8]. RIPC may therefore improve impaired cognitive function in
those with known cardiovascular or metabolic disease [9].
Despite several studies showing statistically signiﬁcant reductions in
surrogate measures of infarct size [10], some clinicians remain ambiva-
lent about the clinical signiﬁcance of these ﬁndings [11]. Modelling of
creatine kinase [12] and tumour necrosis factor alpha [13] have been
used to quantify infarct size in those with ST-elevated myocardialthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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[14].
Recent meta-analyses examined the beneﬁts of IPC for people un-
dertaking PCI, but this work only assessed surrogate measures of myo-
cardial infarct size and acute kidney injury and the latter of these
analyses also considered non-elective PCI [15,16]. There are many
other relevant RIPC outcome measures that have been reported for
which data pooling has not yet been conducted. Other analyses com-
bined data from studies of pre- and post-conditioning, but between
study heterogeneity was high indicating data pooling of these two
slightly different interventions may not be justiﬁed [17,18]. Despite
these previous pooled analyses the clinical signiﬁcance of RIPC remains
in doubt as theﬁndings havenot been comparedwith published thresh-
olds of clinical signiﬁcance [19,20]. We have therefore taken the ap-
proach of limiting our analysis to remote-preconditioning only in
those undertaking elective percutaneous intervention in order to mini-
mize the confounding effects of varied study inclusion criteria and in the
type of preconditioning stimulus.
The aims of this work were to; (i) examine the effects of RIPC on a
range of major adverse cardiac events (MACE) and markers of myocar-
dial and renal damage in patients undertaking elective PCI; (ii) relate
these ﬁndings to established thresholds of clinical signiﬁcance and pro-
vide an evidence based context for RIPC use.
2. Materials & methods
2.1. Search strategy
To identify potential studies systematic searches were carried out
using the following databases: EMBASE, PubMed, Web of Science and
the Cochrane Central Registry of Controlled Trials (CENTRAL). The
search was supplemented by scanning the reference lists of eligible
studies. The search strategy included the key concepts of “remote ische-
mic preconditioning” AND “percutaneous coronary intervention” (see
supplementary Fig. S1). All identiﬁed papers were assessed indepen-
dently by two reviewers. A third reviewer was consulted to resolve dis-
putes. Searches of published papers were conducted up until May 1st,
2015.
2.2. Types of studies to be included
Only randomized controlled trials (RCTs) of RIPC in patients under-
going elective PCI were included. There were no language restrictions.
Animal studies, review papers and non-randomized controlled trials
were excluded. Studies that do not have any of the desired outcome
measures or participants whowere treated by other surgical modalities
such as coronary artery bypass graftingwere excluded. Incomplete data,
or data from an already included study, were excluded. Studies that in-
cluded interventions other than RIPC were excluded.
2.3. Participants/population
This meta-analysis analysed RCTs of both male and female adult
(≥18 years) patientswith coronary artery diseasewhowere undergoing
elective, but not emergency, PCI. Other treatment modalities and inter-
ventions for coronary artery disease such as RIPC in coronary artery by-
pass grafting were excluded.
2.4. Intervention(s), exposure(s)
This meta-analysis considered all RCTs where patients with stable
angina or acute coronary syndrome being treated with PCI were ex-
posed to RIPC. More speciﬁcally all RCTs where the intervention of
expanding a blood pressure cuff or applying a medical tourniquet in a
remote limb was carried out before PCI.2.5. Comparator(s)/control
The meta-analysis utilised RCT's that compare RIPC during percuta-
neous coronary intervention with a usual care control group receiving
sham or no RIPC during percutaneous coronary intervention.
2.6. Search Results
Our initial search found 486 articles. Of these 441 were excluded
based upon title and abstract. Nineteen studies were excluded as they
were not RCTs. Nine studies were excluded because they were trials of
post-conditioning, one study was excluded because it was peri-condi-
tioning and 7 studieswere excluded because theywere studies of emer-
gency PCI (see supplementary Fig. S2). Nine studies [2,21–26,28,29]
were included in our analysis.
2.7. Outcome(s)
The primary outcomes analysed were:
1. Peri-procedural myocardial infarction (MI)
(This was deﬁned differently in the different trials. Ahmed et al. [21]
and Xu et al. [22] deﬁned MI as an increase in cTnT as greater than
three times the 99th percentile URL, whilst Hoole et al. [23] used
the same parameters for cTnI. Ghaemian et al. [24] and Prasad et al.
[25] considered MI as cTnT N0.03 ng/ml. Liu et al. [2] did not report
how they deﬁned MI. Luo et al. [26] deﬁned MI as cTnI N0.2 mg/ml).
2. ST segment deviation
(This was deﬁned as either an elevation or depression of the ST seg-
ment on an ECG of N1 mm).
3. Incidence of post-PCI major adverse cardiac events (MACE) at
6 months
(Ghaemian et al. [24] deﬁned this as hospitalization for acute coro-
nary syndrome, MI, or death due to MI. Hoole et al. [23] deﬁned
this as hospital admissionswith unstable angina/acute coronary syn-
drome, MI, heart failure, and stroke/transient ischemic attack. Liu et
al. [2] deﬁned this as cardiac death, hospital admissions with unsta-
ble angina/acute coronary syndrome, MI, heart failure and stroke/
transient ischemic attack.)
4. Mortality
5. Acute kidney injury
(Deﬁned as an increase in serum creatinine of ≥25% above baseline).
6. C-reactive protein
7. Troponin T
(Measured at 16 h post PCI in Ahmed et al. [21]. Ghaemian et al. [24]
measured this at 12 h and 24 h post PCI with the 24 h measurement
used in this study. Prasad et al. [25] measured this at 8, 16 and 24 h
post PCI with the 24 h measurement used in this study.)
2.8. Risk of bias (quality) assessment
The PEDro scale was used to assess study quality and reporting [27].
2.9. Strategy for data synthesis
Odds ratios will be calculated for dichotomous data. Meta-analyses
will be completed for continuous data by calculating the mean differ-
ence between intervention and control groups from post-intervention
data only. It is an accepted practice to only use post-intervention data
for meta-analysis, but this method assumes that random allocation of
participants always creates intervention groups matched at baseline
for age, disease severity. In the case of elective PCI this will be true as
negligible levels of creatine kinase etc. would be expected at baseline
prior to elective PCI; hence we have excluded emergency PCI studies.
All analyseswere conducted using Revman 5.0 (Nordic Cochrane Centre
Denmark). A ﬁxed effects inverse variance model was used unless
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erogeneity was quantiﬁed using the Cochrane Q test. We used a 5%
level of signiﬁcance and 95% conﬁdence intervals; ﬁgures were pro-
duced using Revman 5.3.3. Results
The nine studies [2,21–26,28,29] included in the analyses had an ag-
gregate of 1253 participants, 630 of which received RIPC and 623 were
control/shamgroupparticipants. Table 1 summarizes the characteristics
of the included studies. Table S1 lists the excluded RCTs and reasons for
exclusion. Seven studies used a sham control group, as opposed to usual
care. Only one study utilized the lower limb for RIPC. The RIPC protocols
were very similar in terms of periods of cuff occlusion and periods of
reperfusion.Table 1
Characteristics of included studies.
Study RIPC protocol Comparator
N RIPC
(control)
Ahmed et al. 2013 Upper limb 3 × 5 min & 5 min
reperfusion
Sham RIPC
(deﬂated cuff)
77 (72)
Egypt
Er et al. 2012 Upper limb 4 × 5 min & 5 min
reperfusion
Sham RIPC (10 mm
Hg)
50 (50)
Germany
Ghaemian et al. 2012 Lower limb 2 × 5 min & 5 min
reperfusion
Sham RIPC
(deﬂated cuff)
40 (40)
Iran
Hoole et al. 2009 Upper limb 3 × 5min & 5 min
reperfusion
Sham RIPC
(deﬂated cuff)
104 (98)
UK
Iliodromitis et al. 2006 Upper limb 3 × 5min & 5 min
reperfusion
Sham RIPC
(deﬂated cuff)
20 (21)
Greece
Liu et al. 2014 Upper limb 3 × 5 min & 5 min
reperfusion
Sham RIPC
(deﬂated cuff)
98 (102)
China
Luo et al. 2013 Upper limb 3 × 5min & 5 min
reperfusion
No RIPC 101 (104)
China
Prasad et al. 2013 Upper limb 3 × 3 min & 3 min
reperfusion
Sham RIPC (10 mm
Hg)
47 (48)
USA
Xu et al. 2014 Upper limb 3 × 5 min & 5 min
reperfusion
No RIPC 102 (98)
China
CK– creatine kinase; CRP – C-reactive protein; EPC - endothelial progenitor cells; GFR – glomeru
percutaneous coronary intervention; RIPC – remote ischaemic pre-conditioning; Urinary NGAL3.1. Peri-procedural myocardial infarction and ST-segment deviation
Seven studies reported the incidence of peri-procedural myocardial
infarction (MI), the odds ratio for the pooled analysis of RIPC versus con-
trol group was 0.72 (95% CI 0.54 to 0.97, p=0.03) suggesting a 28% re-
duced risk of MI in patients receiving RIPC (see Fig. 1). These ﬁndings
were supported by reductions in ST-segment deviation, as the odds
ratio for the pooled analysis of RIPC versus control group was OR 0.42
(95% CI 0.28 to 0.63, p b 0.0001) suggesting a 58% reduction in preva-
lence of ST-segment deviation in patients receiving RIPC (see Fig. 2).3.2. Major adverse coronary events at 6 months
Three studies reported the incidence ofmajor adverse cardiac events
(MACE), the odds ratio for the pooled analysis of RIPC versus controlPopulation Age RIPC (control)
Male % RIPC
(control) All outcome measures
Elective
PCI
54.6 ± 7.8 (53.5 ± 8.8) 87 (86) CK-MB
Troponin T
CRP
Procedural MI
Elective
PCI
73.2 ± 9.1 (72.7 ± 11.4) 68 (74) Acute kidney injury
Creatinine
Cystatin C
Urinary NGAL
Mortality
Elective
PCI
58.8 ± 9.8 (61 ± 9.8) 40 (55) Procedural MI
Troponin T
Intra-procedural
arrhythmia
ST-segment deviation
MACE
Mortality
Elective
PCI
63.2 (61.8) 81 (76) Troponin I
CRP
ST-segment deviation
MACCE
Procedural MI
Creatinine
GFR
Elective
PCI
61 ± 10 (62 ± 8) Not given CK
CK-MB
Troponin I
CRP
Elective
PCI
59.9 ± 16.2 (56.3 ± 14.3) 48 (61) CK
CK-MB
Troponin I
CRP
ST-segment deviation
MACE
Mortility
Elective
PCI
59.2 ± 10.3 (59.3 ± 9.5) 77 (75) Troponin I
Procedural MI
Creatinine
GFR
Elective
PCI
67.2 ± 11.4 (65.1 ± 11) 91 (75) Procedural MI
Troponin T
CK-MB
CRP
Early-, intermediate-,
and late EPCs
MACE
Mortality
Elective
PCI
69.1 ± 3.8 (68.9 ± 2.9) 66 (70) Troponin I
CRP
Creatinine
GFR
Procedural MI
larﬁltration rate;MACE–major adverse coronary events;MI –myocardial infarction; PCI –
– urinary neutrophil gelatinase-associated lipocalin.
Fig. 2. ST-segment deviation.
Fig. 1. Peri-procedural myocardial infarction.
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duced risk of MACE in patients receiving RIPC (see Fig. 3).
3.3. Mortality
Five studies reported the mortality incidence, the odds ratio for the
pooled analysis of RIPC versus control group was 1.00 (95% CI 0.27 to
3.73, p= 1.00) suggesting no signiﬁcantly reduced risk of mortality in
patients receiving RIPC (see Fig. 4).
3.4. Acute kidney injury
Four studies reported the incidence of acute kidney injury, the odds
ratio for the pooled analysis of RIPC versus control group was 0.47 (95%
CI 0.26 to 0.86, p=0.01) suggesting a 53% reduced risk of acute kidney
injury in patients receiving RIPC. (See Fig. 5.)
3.5. Biomarkers of cardiovascular damage and inﬂammation
Troponin-T and C-reactive protein were not signiﬁcantly different be-
tween RIPC and control groups (supplementary Figs. S3 and S4,
respectively).Fig. 4.Mor
Fig. 3.Major adverse3.6. Assessment of study quality
We utilised the Physiotherapy Evidence database (PEDro) scale to
evaluate study quality. Median Pedro score was 7 with 1 study scoring
9, 4 studies scoring 7, 3 studies scored 6 and 1 study scored 5 (Supple-
mentary Table S2).
3.7. Publication bias and study heterogeneity
We assessed publication bias by Egger Plots. There was minimal ev-
idence of bias. Study heterogeneity was assessed by Cochrane Q test,
and was low in all cases except MACE, where it was moderate (51%).
4. Discussion
Our meta-analysis is the ﬁrst to examine the beneﬁts of remote is-
chemic pre-conditioning (RIPC) for people undertaking elective percu-
taneous coronary intervention for outcome measures other than
myocardial infarct size and acute kidney injury. We found RIPC signiﬁ-
cantly reduced the risk of peri-procedural infarct, ST-segment deviation,
major adverse cardiac events (MACE) and acute kidney injury. Thesetality.
coronary events.
Fig. 5. Acute kidney injury.
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had been reported previously.
One of the dilemmas faced by patients confronted with the decision
to undergo non-emergency (elective) PCI is to weigh up the potential
risks of PCI against the likely stabilising beneﬁts. Our work has shown
that RIPC provides a likely mitigating effect for a variety of complica-
tions to elective PCI. Recent work has shown that PCI does not reduce
post-intervention mortality risk as much as cardiac by-pass grafting
(CABG), even after adjusting for confounders [30]. Risk ofmyocardial in-
farction (MI) during PCI has been estimated using cardiac biomarkers as
about 8.6% (95% conﬁdence intervals: 5.8% to 12.2%), with symptomatic
ischemia in about 25% ofMI patients [31]. Taking an evidence-based ap-
proach, our analyses suggest that the risk of MI could be reduced by 28%
from 8.6% to 6.2%. These data imply that the number of patients needed
to be treated to prevent 1 MI is b4. Prevalence data for MACE suggested
12% during PCI [32]. Our analyses suggest RIPC could reduceMACE dur-
ing PCI by 59% to 7.1%.
While our analyses did not suggest a signiﬁcantly reduced risk of
mortality in patients receiving elective RIPC, this may be due to the
small number of deaths reported in the included studies. In the RIPC
groups 5 deaths were recorded, while in the sham/control groups 9
deaths were recorded. Intuitively, we are able to deduce two things
from these data: First, the number of published deaths are too few cur-
rently for analyses to provide statistical signiﬁcance. Second, the num-
ber of deaths in the non-intervention groups is almost twice that of
the RIPC groups, this could be considered clinically signiﬁcant even if
it is not statistically signiﬁcant.
Incidence of acute kidney injury (AKI) during PCI ranges from 6 to
26%, but depends on haemoglobin levels [33]. Using the reported con-
servative prevalence estimate of 6%, our analyses suggest RIPC could re-
duce AKI during PCI by 53% to 3.2%.
RIPC is inexpensive, not time-consuming and easily administered by
staff with minimal training. In addition to the utilization of RIPC for PCI
or CABG, several works have recently reported the use of repeated ses-
sions of RIPC over 1–8 week periods, in order to manage blood pressure
and improve blood ﬂow [5,6].Wenow await results of further trials that
are in progress.
The primary limitation of this work is that relatively few adverse
events exist in randomized, controlled trials reported in the published
literature. A secondary limitation is that studies have used marginal
techniques to establish if myocardial injury has occurred, rather than
established techniques like cardiac MRI or repeated Troponins, or com-
binations of two or more methods.5. Conclusions
Remote ischemic pre-conditioning (RIPC) provides clinically mean-
ingful reductions in major adverse cardiac and renal events for people
undertaking elective percutaneous coronary intervention. These ﬁnd-
ings provide evidence that only a small number of patients (b5) are re-
quired to prevent one adverse event, RIPC is therefore probably under-
utilized.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ctrsc.2016.06.001.Source of funding
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